A Phase II Evaluation of Aflibercept in the Treatment of Recurrent or Persistent Endometrial Cancer: a Gynecologic Oncology Group study

PURPOSE: Aflibercept targets vascular endothelial growth factor and placental growth factor. We evaluated activity and toxicity of aflibercept in recurrent/persistent endometrial cancer patients. Biomarkers and association with clinical characteristics and outcome were explored. METHODS: Eligible pa...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Coleman, Robert L., Sill, Michael W., Lankes, Heather A., Fader, Amanda Nickles, Finkler, Neil J., Hoffman, James S., Rose, Peter G., Sutton, Gregory P., Drescher, Charles W., McMeekin, D. Scott, Hu, Wei, Deavers, Michael, Godwin, Andrew K., Alpaugh, R. Katherine, Sood, Anil K.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3568489/
https://ncbi.nlm.nih.gov/pubmed/22922531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2012.08.020
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky